Methods
LA-SCCHN, oropharynx cancer, tumors
TUMORS, OROPHARYNX CANCER
This study is a multicenter, two-arm, open-label, randomized phase III trial. Patients with LA-SCCHN excluding p16 positive oropharynx cancer are randomized to the standard arm or experimental arm. A total dose of 70 Gy for tumors with concurrent cisplatin at 100 mg/m